Introgen’s Advexin Doubles Survival In Some Head & Neck Cancer Patients

Firm plans end-of-June filing in U.S. and EU for p53 tumor suppressor in recurrent head and neck cancer.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet